Drug Development

Nanologica and Drug Development

Nanologica develops nanoporous silica for drug delivery formulation. Nanologica’s proprietary particles solves problems in pharmaceutical formulations by improving solubility, enhancing bioavailability and protecting Active Pharmaceutical Ingredients (APIs) from degradation.

Nanologica’s drug delivery technology NLAB Silica™ is based on micrometer sized silica particles that contain thousands of nanometer sized pores, inside which most APIs can be placed. In this way the API is protected inside the silica particle and two of the most common issues in drug delivery – poor solubility and instable molecules – may thus be addressed, with an enhanced bioavailability as a result.

NLAB Silica™ is by the US Food and Drug Administration a GRAS (Generally Recognized As Safe) approved excipient consisting of nanoporous amorphous silica with tuneable particle and pore size.

Dissolution of API loaded into NLAB Silica™

Nanologica’s drug delivery technology NLAB Spiro™ is adapted for  inhalation. The size of the nanoporous microspheres is between 2 to 5 µm and tailored to reach the desired part of the lung – the smaller particles, the further into the lung the particle containing the API can reach.  

Nanologica’s technology platforms enables formulation of combined drugs, as particles loaded with different APIs may be formulated together. The platforms are continuously being developed in order to suit various pharmaceutical projects with different formulation challenges and administration routes.

Nanologica’s business model includes licensing agreements/ technology transfer, feasibility studies, fee for service contracts as well as development of own assets.